BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11236957)

  • 41. Expression of p16/Ki-67 in ASC-US/LSIL or Normal Cytology with Presence of Oncogenic HPV DNA.
    Solares C; Velasco J; Álvarez-Ruiz E; González-Fernández L; Encinas AI; Astudillo A; Schneider J
    Anticancer Res; 2015 Nov; 35(11):6291-5. PubMed ID: 26504065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. P16 immunostaining and HPV testing in histological specimens from the uterine cervix.
    Capobianco G; Marras V; Wenger JM; Santeufemia DA; Ambrosini G; Lutzoni R; Dessole M; Cherchi PL
    Eur J Gynaecol Oncol; 2013; 34(3):227-30. PubMed ID: 23967551
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical efficacy of p16/Ki-67 dual-stained cervical cytology in secondary prevention of cervical cancer.
    Celewicz A; Celewicz M; Wężowska M; Chudecka-Głaz A; Menkiszak J; Urasińska E
    Pol J Pathol; 2018; 69(1):42-47. PubMed ID: 29895125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The evaluation of p16INK4a immunoexpression/immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples.
    Nasioutziki M; Daniilidis A; Dinas K; Kyrgiou M; Valasoulis G; Loufopoulos PD; Paraskevaidis E; Loufopoulos A; Karakitsos P
    Int J Gynecol Cancer; 2011 Jan; 21(1):79-85. PubMed ID: 21330832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening.
    Wentzensen N; Fetterman B; Tokugawa D; Schiffman M; Castle PE; Wood SN; Stiemerling E; Poitras N; Lorey T; Kinney W
    Cancer Cytopathol; 2014 Dec; 122(12):914-20. PubMed ID: 25132656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Good performance of p16/Ki-67 dual-stain cytology for detection and post-treatment surveillance of high-grade CIN/VAIN in a prospective, cross-sectional study.
    Liu W; Gong J; Xu H; Zhang D; Xia N; Li H; Song K; Lv T; Chen Y; Diao Y; Jao J; Dai S; Zhao P; Yao Q
    Diagn Cytopathol; 2020 Jul; 48(7):635-644. PubMed ID: 32275355
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Using p16 immunohistochemistry to classify morphologic cervical intraepithelial neoplasia 2: correlation of ambiguous staining patterns with HPV subtypes and clinical outcome.
    Liu Y; Alqatari M; Sultan K; Ye F; Gao D; Sigel K; Zhang D; Kalir T
    Hum Pathol; 2017 Aug; 66():144-151. PubMed ID: 28705710
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The role of HPV E6/E7 mRNA combined with P16/ki67 immunocytochemistry in the diagnosis of atypical squamous cells of undetermined significance(ASCUS)].
    Zhan X; Wang S; Wu X; Qiu X; Li F; Zeng Y; Chen Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Oct; 34(10):937-941. PubMed ID: 30554588
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia.
    Riethdorf L; Riethdorf S; Lee KR; Cviko A; Löning T; Crum CP
    Hum Pathol; 2002 Sep; 33(9):899-904. PubMed ID: 12378514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Loss of Fhit expression as a potential marker of malignant progression in preinvasive squamous cervical cancer.
    Butler D; Collins C; Mabruk M; Leader MB; Kay EW
    Gynecol Oncol; 2002 Aug; 86(2):144-9. PubMed ID: 12144820
    [TBL] [Abstract][Full Text] [Related]  

  • 51. p16INK4a immunoexpression: surrogate marker of high-risk HPV and high-grade cervical intraepithelial neoplasia.
    Kalof AN; Cooper K
    Adv Anat Pathol; 2006 Jul; 13(4):190-4. PubMed ID: 16858153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Makorin Ring Finger Protein 1 as Adjunctive Marker in Liquid-based Cervical Cytology.
    Lee M; Chang MY; Shin HY; Shin E; Hong SW; Kim KM; Chay DB; Cho H; Kim JH
    Medicine (Baltimore); 2016 Jan; 95(3):e2425. PubMed ID: 26817873
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of P16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology.
    Carozzi F; Cecchini S; Confortini M; Becattini V; Cariaggi MP; Pontenani G; Sani C; Ciatto S
    Cancer; 2006 Apr; 108(2):119-23. PubMed ID: 16411180
    [TBL] [Abstract][Full Text] [Related]  

  • 54. From Papanicolaou to papillomaviruses: evolving challenges in cervical cancer screening in the era of human papillomavirus vaccination.
    Safaeian M; Sherman ME
    J Natl Cancer Inst; 2013 Oct; 105(20):1524-6. PubMed ID: 24096622
    [No Abstract]   [Full Text] [Related]  

  • 55. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.
    Cuschieri K; Wentzensen N
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2536-45. PubMed ID: 18842994
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual immunostaining of cervical cytology specimens with atypical squamous cells for p16/Ki-67 does not exclude the existence of a high-grade squamous intraepithelial lesion.
    Koo YJ; Hahn HS; Lee IH; Lim KT; Lee KH; Kim HS; Kim TJ; Chun YK; Kim HS; Hong SR
    Virchows Arch; 2013 Nov; 463(5):689-96. PubMed ID: 24081504
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Role of p16INK4a as a biomarker in liquid-based cervical cytology screening].
    Xu T; Lu HJ; He YF
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):211-4. PubMed ID: 18756939
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer.
    Branca M; Ciotti M; Giorgi C; Santini D; Di Bonito L; Costa S; Benedetto A; Bonifacio D; Di Bonito P; Paba P; Accardi L; Syrjänen S; Favalli C; Syrjänen K;
    Eur J Obstet Gynecol Reprod Biol; 2007 Feb; 130(2):223-31. PubMed ID: 17098349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Utility of CINtec PLUS Triage in Equivocal Cervical Cytology and Human Papillomavirus Primary Screening.
    McMenamin M; McKenna M; McDowell A
    Am J Clin Pathol; 2018 Oct; 150(6):512-521. PubMed ID: 30169728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
    Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
    JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.